Results 121 to 130 of about 21,171,014 (388)

Management of acquired haemophilia A [PDF]

Journal of Thrombosis and Haemostasis, 2011
Acquired haemophilia A is an auto-immune disease caused by an inhibitory antibody to factor VIII. The pattern of bleeding varies but patients remain at risk of life threatening bleeding until the inhibitor has been eradicated. The cornerstones of management are; rapid and accurate diagnosis, control of bleeding, investigation for an underlying cause ...
openaire   +2 more sources

Organization of a reference haemophilia unit and its change of activity during the COVID‐19 pandemic [PDF]

, 2020
María Fernanda Martínez García, Olga Benítez, Eva Álvarez Martínez, J.C. Juárez Giménez, Carmen Fernandez Sarmiento, Milagros Suito Alcántara, Núria Bonet, Raquel Cardona Lopez, Gloria Iacoboni Garcia‐Calvo, Mercedes Gironella   +9 more
openalex   +1 more source

Suboptimal screening and correction of maternal iron deficiency anaemia in the general population and in inherited bleeding disorders: A population‐based cohort study

British Journal of Haematology, EarlyView.
Summary Iron deficiency anaemia (IDA) is associated with adverse pregnancy outcomes globally. Women with inherited bleeding disorders are at increased risk, with scarce data on rates of IDA screening and correction during pregnancy. The impact of correction on outcomes is unclear.
Arafat Ul Alam, Padma Kaul, Venu Jain, Cynthia Wu, Haowei (Linda) Sun   +4 more
wiley   +1 more source

The UK register of HIV seroconverters: Methods and analytical issues [PDF]

, 2009
A Register of HIV-infected persons who have had a negative antibody test within 3 years of their first antibody positive test (seroconverters) is being set up in the UK to monitor the distribution of times from HIV seroconversion to AIDS (the incubation ...
Babiker, A, Beral, V, Brettle, RP, Carne, C, Darbyshire, JH, Evans, BG, Gilson, RJC, Goldberg, D, Hawkins, DA, Jeffries, D, Johnson, AM, Johnson, MA, McMichael, AJ, Mortimer, PP, Phillips, AN, Porter, K, Pozniak, A, Weber, J, Wellsteed, S   +18 more
core   +1 more source

Recombinant factor VIII Fc fusion protein for immune tolerance induction in patients with severe haemophilia A with inhibitors—A retrospective analysis

Haemophilia, 2018
Immune tolerance induction (ITI) is the gold standard for eradication of factor VIII inhibitors in severe haemophilia A; however, it usually requires treatment for extended periods with associated high burden on patients and healthcare resources.
M. Carcao, A. Shapiro, Janice M. Staber, Nina Hwang, C. Druzgal, Kenneth Lieuw, M. Belletrutti, Courtney D. Thornburg, Sanjay Ahuja, J. Morales-Arias, Jennifer A. Dumont, G. Miyasato, Elisa Tsao, N. Jain, S. Pipe   +14 more
semanticscholar   +1 more source

Safety and Efficacy of Damoctocog Alfa Pegol in Previously Treated Children Aged 7 to < 12 Years With Severe Haemophilia A in the Phase 3, Open Label Alfa‐PROTECT Main Study

European Journal of Haematology, EarlyView.
ABSTRACT Background In the earlier PROTECT VIII Kids study (NCT01775618), damoctocog alfa pegol was efficacious for prevention and treatment of bleeds in children aged < 12 years with severe haemophilia A. Objective Assess the safety of damoctocog alfa pegol, including hypersensitivity and loss of efficacy (LoE) due to an immune response to ...
Margareth C. Ozelo, Matteo Luciani, Heidi Glosli, Kaan Kavakli, Nasrin Samji, Gregory C. Makris, Claudia Tueckmantel, Monika Maas Enriquez, Luciana C. Oliveira, Shveta Gupta, Mario Guillermo Arbesú, Mauro Davoli, Anthony K. C. Chan, Maria E. Mancuso   +13 more
wiley   +1 more source

Prothrombotic risk mutations and polymorphisms in patients with hemophilia A – a preliminary study / Polimorfismele și mutațiile cu risc protrombotic la pacienții cu hemofilie A - studiu preliminar

Romanian Journal of Laboratory Medicine, 2015
Introducere. Necesitatea explicării heterogenităţii clinice la pacienţii cu hemofilie (PcH), cu acelaşi grad de severitate sau cu aceeaşi mutaţie, a determinat preocupările de evaluare a coexistenţei polimorfismelor şi mutațiilor cu risc protrombotic ...
Boeriu Estera, Şerban Margit, Neuner Bruno, Arghirescu Smaranda Teodora, Ioniţă Hortensia, Ursu Cristina Emilia, Ritli Ladislau, Talpoş Şerban, Jinca Cristian, Pătraşcu Jenel Marian   +9 more
doaj   +1 more source

Report of Two Cases of Acquired Idiopathic Haemophilia [PDF]

, 2021
Clara Silva, Mariana Pacheco, João Enes Silva, Edite Pereira, Jorge Almeida   +4 more
openalex   +1 more source

Recombinant porcine sequence factor VIII (rpFVIII) for acquired haemophilia A: practical clinical experience of its use in seven patients

Haemophilia, 2017
A recombinant porcine factor VIII B‐domain‐deleted product (rpFVIII; OBIZUR, Baxalta Incorporated, Deerfield, IL 60015, USA) was recently approved for treatment of bleeding episodes in adults with acquired haemophilia A (AHA) in the United States.
M. Tarantino, A. Cuker, B. Hardesty, J. Roberts, M. Sholzberg   +4 more
semanticscholar   +1 more source

Efficacy and Safety of Prophylaxis With a Plasma‐Derived von Willebrand Factor/Factor VIII Concentrate (Wilate) in Patients With Type 3 von Willebrand Disease—A WIL‐31 Study Sub‐Analysis

European Journal of Haematology, EarlyView.
ABSTRACT Objectives The WIL‐31 study demonstrated efficacy and safety of prophylaxis with the plasma‐derived von Willebrand factor/factor VIII concentrate wilate in von Willebrand disease (VWD) of all types and was the only prospective study with an on‐demand run‐in study as an intra‐individual comparator.
Claudia Djambas Khayat, Leonid Dubey, Adlette Inati, Toshko Lissitchkov, Dzmitry Novik, Elina Peteva, Robert F. Sidonio Jr, Ali T. Taher, Kateryna V. Vilchevska, Vladimir Vdovin, Ana Boban   +10 more
wiley   +1 more source